Key Takeaways
- • R1 Therapeutics expanded its Series A financing to $80.5 million, building on an oversubscribed $77.5 million round announced in March 2026, with new capital from Samsara BioCapital.
- • The expanded syndicate now includes six institutional investors: Abingworth, DaVita Venture Group, F-Prime, Curie.Bio, SNMA Capital (formerly Symbiosis Capital Management), and U.S. Renal Care, signaling strong institutional conviction in the company's pipeline.
- • R1 Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for kidney disease, a large and underserved patient population.
- • The oversubscription and expansion of the Series A indicates robust investor demand for novel kidney disease therapeutics and validates R1's clinical approach.
Summary
R1 Therapeutics announced an expansion of its Series A financing round to $80.5 million, with Samsara BioCapital joining the investor syndicate. The funding expansion follows the company's oversubscribed $77.5 million Series A round announced in March 2026, demonstrating sustained investor appetite for the company's pipeline.
The Redwood City–based clinical-stage biopharmaceutical company is developing first-in-class therapies targeting kidney disease, a therapeutic area with significant unmet medical need. The company's focus on renal disease addresses a patient population that faces limited treatment options and represents a substantial market opportunity for novel therapeutics.
The expanded Series A syndicate comprises six institutional backers: Abingworth, DaVita Venture Group, F-Prime, Curie.Bio, SNMA Capital (previously known as Symbiosis Capital Management), and U.S. Renal Care. The participation of DaVita Venture Group and U.S. Renal Care, both entities with deep operational expertise in renal care delivery, suggests potential strategic alignment beyond capital provision. The involvement of established venture firms including Abingworth and F-Prime further reinforces the institutional quality of the funding round.
The oversubscription of the initial Series A tranche and subsequent expansion reflects confidence in R1's clinical strategy and management team. For institutional investors monitoring the biopharmaceutical venture landscape, the funding expansion indicates a maturing clinical program with sufficient investor conviction to warrant additional capital deployment before anticipated clinical milestones.
The Redwood City–based clinical-stage biopharmaceutical company is developing first-in-class therapies targeting kidney disease, a therapeutic area with significant unmet medical need. The company's focus on renal disease addresses a patient population that faces limited treatment options and represents a substantial market opportunity for novel therapeutics.
The expanded Series A syndicate comprises six institutional backers: Abingworth, DaVita Venture Group, F-Prime, Curie.Bio, SNMA Capital (previously known as Symbiosis Capital Management), and U.S. Renal Care. The participation of DaVita Venture Group and U.S. Renal Care, both entities with deep operational expertise in renal care delivery, suggests potential strategic alignment beyond capital provision. The involvement of established venture firms including Abingworth and F-Prime further reinforces the institutional quality of the funding round.
The oversubscription of the initial Series A tranche and subsequent expansion reflects confidence in R1's clinical strategy and management team. For institutional investors monitoring the biopharmaceutical venture landscape, the funding expansion indicates a maturing clinical program with sufficient investor conviction to warrant additional capital deployment before anticipated clinical milestones.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.